PRESS RELEASE
 
Evolva receives approval for Veri-teTM Resveratrol in Taiwan

Reinach, 25 July 2023 – Evolva (SIX: EVE) a pioneer in the field of natural molecules and industrial biotech, has received approval for its Veri-te^TM Resveratrol from the Taiwanese Food and Drug Administration (TFDA) for use as an ingredient in foods and dietary supplements.

The approval is an important milestone as it opens up Taiwan as a further South-East Asian market after the Philippines, Malaysia and Vietnam where Veri-te^TM Resveratrol is already available for use in foods and dietary supplements. The approval was obtained in close partnership with Champion Co. Ltd., Evolva’s Taiwanese distribution partner, who supported Evolva throughout the registration process. Champion Co. Ltd. will also accompany market introduction. The launch is scheduled for 28^th of July in the format of a technical seminar during Bio Asia Taiwan in Taipei, a key tradeshow in the region.

Anne De Vos, Chief Commercial Officer of Evolva, comments: ”Our Veri-te^TM Resveratrol, is a multi-functional ingredient with proven health benefits. We are excited to now also be able to offer this product for use in foods and dietary supplements in Taiwan. We will work closely with our trusted partner Champion Co. Ltd., to develop market entry and address the exciting potential the Taiwanese market offers. Over a 3-5 year time horizon, we estimate the sales potential in this market to be in the mid single-digit USD million range. Veri-te^TM Resveratrol is a main pillar of Evolva’s Health Ingredients business and a key focus area to boost our commercial performance.”
 

Important dates
24 August 2023  Half-year 2023 results

Contact
Doris Rudischhauser
Head of Investor Relations and Corporate Communications
+41 79 410 81 88
dorisr@evolva.com
 

About Veri-teTM Resveratrol
Resveratrol is a polyphenolic compound that occurs naturally in plants such as grapes, peanuts, cranberries and other berries, albeit at low concentrations. Evolva’s Veri-te^TM Resveratrol is a nature-based high-purity ingredient, made via fermentation, which ensures a stable, traceable and reliable supply. The ingredient is offered in different formats such as a cold-water dispersible or an oil and water-soluble resveratrol and is sold for use in dietary supplements, functional beverages, cosmetics, pharma applications and animal health markets.

About Evolva
Evolva is a Swiss biotech company focused on the research, development and commercialization of ingredients based on nature. We have leading businesses in Flavors and Fragrances, Health Ingredients and Health Protection. Evolva’s employees, half of which are women, are dedicated to make the best products that can contribute to health, wellness and sustainability. Find out more at evolva.com and connect with us on LinkedIn.

Disclaimer
This announcement is not an offer of securities into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered, pledged, sold, delivered or otherwise transferred, directly or indirectly, in the United States, except pursuant to an exemption from, or transaction not subject to, the registration requirements of the Securities Act. No public offering of securities is being made in the United States. Further, the securities referred to herein have not been and will not be registered under the applicable securities laws of Canada, Australia or Japan or under the applicable securities laws of any other jurisdiction where to do so might constitute a violation of such laws.             
This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.